Literature DB >> 19903788

Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features.

Simone T Sredni1, Samantha Gadd, Chiang-Ching Huang, Norman Breslow, Paul Grundy, Daniel M Green, Jeffrey S Dome, Robert C Shamberger, J Bruce Beckwith, Elizabeth J Perlman.   

Abstract

PURPOSE: Recent studies suggest that children <24 months with stage I favorable histology Wilms tumors <550 g [very low risk Wilms tumors (VLRWT)] have an excellent prognosis when treated with nephrectomy only, without adjuvant chemotherapy. The identification of risk categories within VLRWT may enable refinement of their definition and optimization of their therapy. EXPERIMENTAL
DESIGN: To define biologically distinct subsets, global gene expression analysis was done on 39 VLRWT that passed all quality-control parameters and the clusters identified were validated in an independent set of 11 VLRWT. Validation of select differentially expressed genes was done with immunohistochemistry on a tissue microarray from 20 of 39 tumors. Loss of heterozygosity (LOH) for 11p15, 1p, and 16q was analyzed in 52 tumors using PCR.
RESULTS: Two distinctive clusters were identified. One cluster included 9 tumors with epithelial differentiated tubular histology, paucity of nephrogenic rests, lack of LOH for 1p, 16q, and 11p, absence of relapse, and a unique gene expression profile consistent with arrest following mesenchymal-to-epithelial transition. The second cluster included 13 tumors with mixed histology, intralobar nephrogenic rests, and decreased expression of WT1. Three of 6 relapses occurred in this cluster. Of 43 informative tumors, 11p LOH was present in 5 of 5 relapses and 11 of 38 nonrelapses.
CONCLUSIONS: Two subsets comprising a total of 56% of VLRWT are identified that have pathogenetic and molecular differences and apparent differences in risk for relapse. If these predictors can be prospectively validated, this would enable the refinement of clinical stratification and less arbitrary definition of VLRWT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903788      PMCID: PMC2782600          DOI: 10.1158/1078-0432.CCR-09-0312

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  32 in total

1.  Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney.

Authors:  Michelle Self; Oleg V Lagutin; Beth Bowling; Jaime Hendrix; Yi Cai; Gregory R Dressler; Guillermo Oliver
Journal:  EMBO J       Date:  2006-10-12       Impact factor: 11.598

Review 2.  Wilms tumor genetics.

Authors:  V Huff
Journal:  Am J Med Genet       Date:  1998-10-02

3.  Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology.

Authors:  V Schumacher; S Schneider; A Figge; G Wildhardt; D Harms; D Schmidt; A Weirich; R Ludwig; B Royer-Pokora
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

4.  A gene expression signature for relapse of primary wilms tumors.

Authors:  Wenliang Li; Patricia Kessler; Herman Yeger; Jennifer Alami; Anthony E Reeve; Rosemary Heathcott; Jane Skeen; Bryan R G Williams
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

5.  Gene expression profile associated with response to doxorubicin-based therapy in breast cancer.

Authors:  Maria Aparecida Azevedo Koike Folgueira; Dirce Maria Carraro; Helena Brentani; Diogo Ferreira da Costa Patrão; Edson Mantovani Barbosa; Mário Mourão Netto; José Roberto Fígaro Caldeira; Maria Lucia Hirata Katayama; Fernando Augusto Soares; Célia Tosello Oliveira; Luiz Fernando Lima Reis; Jane Haruko Lima Kaiano; Luiz Paulo Camargo; Ricardo Zorzetto Nicoliello Vêncio; Igor Moysés Longo Snitcovsky; Fabiana Baroni Alves Makdissi; Paulo José da Silva e Silva; João Carlos Guedes Sampaio Góes; Maria Mitzi Brentani
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

6.  Classification of malignant pediatric renal tumors by gene expression.

Authors:  Chiang-Ching Huang; Colleen Cutcliffe; Cheryl Coffin; Poul H B Sorensen; J Bruce Beckwith; Elizabeth J Perlman
Journal:  Pediatr Blood Cancer       Date:  2006-06       Impact factor: 3.167

7.  Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.

Authors:  Paul E Grundy; Norman E Breslow; Sierra Li; Elizabeth Perlman; J Bruce Beckwith; Michael L Ritchey; Robert C Shamberger; Gerald M Haase; Giulio J D'Angio; Milton Donaldson; Max J Coppes; Marcio Malogolowkin; Patricia Shearer; Patrick R M Thomas; Roger Macklis; Gail Tomlinson; Vicki Huff; Daniel M Green
Journal:  J Clin Oncol       Date:  2005-08-29       Impact factor: 44.544

8.  PAPPA2, an enzyme that cleaves an insulin-like growth-factor-binding protein, is a candidate gene for a quantitative trait locus affecting body size in mice.

Authors:  Julian K Christians; Andreas Hoeflich; Peter D Keightley
Journal:  Genetics       Date:  2006-05-15       Impact factor: 4.562

9.  Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.

Authors:  Hiroyuki Izumi; Jun Inoue; Sana Yokoi; Hiroshi Hosoda; Tatsuhiro Shibata; Makoto Sunamori; Setsuo Hirohashi; Johji Inazawa; Issei Imoto
Journal:  Hum Mol Genet       Date:  2005-03-03       Impact factor: 6.150

10.  CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.

Authors:  Chi-Ming Li; Connie E Kim; Adam A Margolin; Meirong Guo; Jimmy Zhu; Jacqueline M Mason; Terrence W Hensle; Vundavalli V V S Murty; Paul E Grundy; Eric R Fearon; Vivette D'Agati; Jonathan D Licht; Benjamin Tycko
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

View more
  16 in total

1.  WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study.

Authors:  Elizabeth J Perlman; Paul E Grundy; James R Anderson; Lawrence J Jennings; Daniel M Green; Jeffrey S Dome; Robert C Shamberger; E Cristy Ruteshouser; Vicki Huff
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

2.  Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.

Authors:  Conrad V Fernandez; Elizabeth J Perlman; Elizabeth A Mullen; Yueh-Yun Chi; Thomas E Hamilton; Kenneth W Gow; Fernando A Ferrer; Douglas C Barnhart; Peter F Ehrlich; Geetika Khanna; John A Kalapurakal; Tina Bocking; Vicky Huff; Jing Tian; James I Geller; Paul E Grundy; James R Anderson; Jeffrey S Dome; Robert C Shamberger
Journal:  Ann Surg       Date:  2017-04       Impact factor: 12.969

Review 3.  Wilms tumor.

Authors:  Andrew M Davidoff
Journal:  Adv Pediatr       Date:  2012

Review 4.  Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor.

Authors:  Jeffrey S Dome; Elizabeth A Mullen; David B Dix; Eric J Gratias; Peter F Ehrlich; Najat C Daw; James I Geller; Murali Chintagumpala; Geetika Khanna; John A Kalapurakal; Lindsay A Renfro; Elizabeth J Perlman; Paul E Grundy; Conrad V Fernandez
Journal:  J Natl Compr Canc Netw       Date:  2021-08-01       Impact factor: 11.908

5.  Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.

Authors:  Conrad V Fernandez; Elizabeth A Mullen; Yueh-Yun Chi; Peter F Ehrlich; Elizabeth J Perlman; John A Kalapurakal; Geetika Khanna; Arnold C Paulino; Thomas E Hamilton; Kenneth W Gow; Zelig Tochner; Fredric A Hoffer; Janice S Withycombe; Robert C Shamberger; Yeonil Kim; James I Geller; James R Anderson; Paul E Grundy; Jeffrey S Dome
Journal:  J Clin Oncol       Date:  2017-12-06       Impact factor: 44.544

Review 6.  Children's Oncology Group's 2013 blueprint for research: renal tumors.

Authors:  Jeffrey S Dome; Conrad V Fernandez; Elizabeth A Mullen; John A Kalapurakal; James I Geller; Vicki Huff; Eric J Gratias; David B Dix; Peter F Ehrlich; Geetika Khanna; Marcio H Malogolowkin; James R Anderson; Arlene Naranjo; Elizabeth J Perlman
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

7.  Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children's Oncology Group study AREN03B2.

Authors:  Lauren N Parsons; Elizabeth A Mullen; James I Geller; Yueh-Yun Chi; Geetika Khanna; Richard D Glick; Jennifer H Aldrink; Kelly L Vallance; Yeonil Kim; Conrad V Fernandez; Jeffrey S Dome; Elizabeth J Perlman
Journal:  Cancer       Date:  2020-04-08       Impact factor: 6.860

Review 8.  Biomarkers for Wilms Tumor: A Systematic Review.

Authors:  Eugene B Cone; Stewart S Dalton; Megan Van Noord; Elizabeth T Tracy; Henry E Rice; Jonathan C Routh
Journal:  J Urol       Date:  2016-05-31       Impact factor: 7.450

9.  Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.

Authors:  Samantha Gadd; Vicki Huff; Chiang-Ching Huang; E Cristy Ruteshouser; Jeffrey S Dome; Paul E Grundy; Norman Breslow; Lawrence Jennings; Daniel M Green; J Bruce Beckwith; Elizabeth J Perlman
Journal:  Neoplasia       Date:  2012-08       Impact factor: 5.715

Review 10.  Genetic variation frequencies in Wilms' tumor: A meta-analysis and systematic review.

Authors:  Changkai Deng; Rong Dai; Xuliang Li; Feng Liu
Journal:  Cancer Sci       Date:  2016-03-18       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.